Targeted Anti‐Inflammatory Nanozymes with Pro‐Angiogenic Activity for Myocardial Infarction Therapy
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202404979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Wenling Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Hauptthemen laut MEDLINE: Myocardial Infarction, Nanoparticles, Anti-Inflammatory Agents, Angiogenesis Inducing Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Myocardial infarction (MI) poses a significant threat to human health. Current treatments emphasize early revascularization to restore blood supply to the myocardium, often overlooking the extensive oxidative damage and autophagy dysfunction resulting from reactive oxygen species (ROS) release after MI. Therefore, timely and effective interventions to clear ROS in the early stages of MI are crucial for inhibiting the MI pathological progression and restoring cardiac function. This study constructed a ROS‐responsive biomimetic nanoparticle (PNP@Nb 2 C‐MSN) by integrating niobium carbide MXenes (Nb 2 C) onto mesoporous silica nanoparticle (MSN) coated with platelet membrane. During the MI acute phase, these nanoparticles are targeted and delivered to the infarcted heart via intravenous injection. The MSN mesoporous structure enhances the ROS scavenging capacity of Nb 2 C, eliminating excess ROS in the infarct region and inhibiting the oxidative stress progression. Silicon ions released from MSN further promote angiogenesis within the infarct region. PNP@Nb 2 C‐MSN reduces inflammation by downregulating the NF‐κB pathway and enhances autophagy by activating the AMPK pathway, thereby blocking pathological microenvironmental progression after MI and improving cardiac function. In vitro and in vivo results highlight the therapeutic potential of PNP@Nb 2 C‐MSN in MI, offering a promising MI treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Hubei Provincial Engineering Research Center for Immunological Diagnosis and Therapy of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Chin…
- Key Laboratory of Biological Targeted Therapy (Huazhong University of Science and Technology), Ministry of Education, Wuhan, Hubei, 430022, China.
- Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, P. R. China.
- Department of Spine Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
ORCID-Profile: Yumiao Wei
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, W., Li, X., Lei, J., Jiang, S., Sun, J., Liu, Q., Zhang, R., Zheng, C., Guo, X., & Wei, Y. (2025). Targeted Anti‐Inflammatory Nanozymes with Pro‐Angiogenic Activity for Myocardial Infarction Therapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404979
Vancouver
Yang W, Li X, Lei J, Jiang S, Sun J, Liu Q, et al. Targeted Anti‐Inflammatory Nanozymes with Pro‐Angiogenic Activity for Myocardial Infarction Therapy. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404979
BibTeX
@article{Yang2025,
author = {Yang, Wenling and Li, Xuelian and Lei, Jie and Jiang, Shijiu and Sun, Jinpeng and Liu, Qingyi and Zhang, Ruiyu and Zheng, Chuansheng and Guo, Xiaopeng and Wei, Yumiao},
title = {Targeted Anti‐Inflammatory Nanozymes with Pro‐Angiogenic Activity for Myocardial Infarction Therapy},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202404979}
}
EUVIMED